Literature DB >> 8032652

The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.

D J Trezise1, I Kennedy, P P Humphrey.   

Abstract

1. We have previously found that the P2x-purinoceptor agonist, alpha, beta-methylene adenosine 5'-triphosphate (alpha, beta-methylene ATP), depolarizes the rat cervical vagus nerve, measured with a 'grease-gap' extracellular recording technique. This effect was attenuated by the P2 purinoceptor antagonist, suramin. In the present study we have investigated in more detail the antagonism produced by suramin and have also investigated the actions of two other putative P2 purinoceptor antagonists, cibacron blue and pyridoxal-phosphate-6-azophenyl-2', 5'-disulphonic acid (iso-PPADS). Furthermore, we have studied the interactions between suramin and cibacron blue or iso-PPADS in an attempt to determine whether these antagonists act at a common receptor site. 2. Suramin (1 x 10(-5)-1 x 10(-4) M) produced reversible, concentration-related rightward displacements of the concentration-effect curve to alpha, beta-methylene ATP. Schild analysis of this antagonism yielded a pA2 value of 5.90 with a slope value of 0.47. 3. Cibacron blue (3 x 10(-5)-1 x 10(-4) M) also antagonized depolarizations induced by alpha, beta-methylene ATP. The antagonistic effects of cibacron blue were slow to reach equilibrium but could be readily reversed on washout. At low concentrations for antagonism, cibacron blue (1 x 10(-5) M and 3 x 10(-5) M) produced enhancement of the maximal response to alpha, beta-methylene ATP. At the highest concentration tested (1 x 10(-4) M) the concentration-effect curve to alpha, beta-methylene ATP was shifted to the right in a parallel manner, yielding a pKB estimate of 4.96. 4. Iso-PPADS (1 X 10-6 1 X 10-5- M) produced a concentration-related depression in the maxima ofthe concentration-effect curves to alpha,beta-methylene ATP. Analysis of these data by a double reciprocal plot yielded a pKB estimate of 6.02. This profile of insurmountable antagonism could not be attributed to irreversible binding of iso-PPADS to the receptor since the effect of iso-PPADS could be reversed on washing, albeit slowly.5. In the presence of suramin (1 x 10-4 M), cibacron blue (1 x 10-4 M) produced no further rightward displacement of the alpha,beta-methylene ATP concentration-effect curve. The mean agonist concentration ratios in the presence of suramin or cibacron blue alone (11.7 and 10.3, respectively) were not significantly different from the mean concentration-ratio in the presence of both antagonists (11.8). This finding suggests that high concentrations of alpha,beta-methylene ATP activate a receptor population which is resistant to blockade by either antagonist.6. The antagonistic effect of iso-PPADS (1 x 10-5 M) was partially attenuated by suramin (1I x 10-4 M).It is possible that this interaction reflects a slow dissociation of iso-PPADS from the receptor with which suramin and alpha,beta-methylene ATP interact.7. Suramin, cibacron blue or iso-PPADS had no marked effect on depolarization produced by 5-hydroxytryptamine (5-HT, 1 x 10-7-3 x 10-5 M), indicating their specificity in antagonizing responses to alpha, beta-methylene ATP.8. Responses to alpha,beta-methylene ATP were not antagonized by 8-para-sulphophenyltheophylline (3 x 10-5M), ondansetron (1 x 10-7 M), bicuculline (1 x I0-5 M), phentolamine (1 X 10-6 M) or hexamethonium(1 X 10-4 M), which are antagonists at P1-purinoceptors, 5-HT3 receptors, GABAA receptors, a-adrenoceptors and nicotinic cholinoceptors, respectively, thereby excluding the involvement of these receptors.Indomethacin (3 X 10-6 M) had no effect on responses to alpha,beta-methylene ATP.9. The results obtained with three purinoceptor antagonists confirm and extend our original supposition that alpha,beta-methylene ATP-induced depolarization of the rat vagus nerve is mediated predominantly via P2 purinoceptors, thought to be of the P2,X subtype. The finding that responses induced by high concentrations of agonist were resistant to blockade by suramin and cibacron blue, but could be attenuated by iso-PPADS, adds further weight to our speculation that the purinoceptor population in the rat vagus nerve is heterogeneous.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032652      PMCID: PMC1910282          DOI: 10.1111/j.1476-5381.1994.tb13065.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses.

Authors:  G Lambrecht; T Friebe; U Grimm; U Windscheif; E Bungardt; C Hildebrandt; H G Bäumert; G Spatz-Kümbel; E Mutschler
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

2.  THE UPTAKE OF ATROPINE AND RELATED DRUGS BY INTESTINAL SMOOTH MUSCLE OF THE GUINEA-PIG IN RELATION TO ACETYLCHOLINE RECEPTORS.

Authors:  W D PATON; H P RANG
Journal:  Proc R Soc Lond B Biol Sci       Date:  1965-08-24

3.  Effects of suramin on the concentration--response relationship of alpha, beta-methylene ATP on the mouse vas deferens.

Authors:  A G Blakeley; J E Brockbank; S S Kelly; S A Petersen
Journal:  J Auton Pharmacol       Date:  1991-02

4.  The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues.

Authors:  A Butler; C J Elswood; J Burridge; S J Ireland; K T Bunce; G J Kilpatrick; M B Tyers
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

Review 5.  P2-purinoceptor antagonists.

Authors:  J S Fedan; S J Lamport
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 6.  Further subclassification of ATP receptors based on agonist studies.

Authors:  S E O'Connor; I A Dainty; P Leff
Journal:  Trends Pharmacol Sci       Date:  1991-04       Impact factor: 14.819

7.  Suramin: a selective inhibitor of purinergic neurotransmission in the rat isolated vas deferens.

Authors:  N Mallard; R Marshall; A Sithers; B Spriggs
Journal:  Eur J Pharmacol       Date:  1992-09-10       Impact factor: 4.432

8.  ATP receptor-mediated synaptic currents in the central nervous system.

Authors:  F A Edwards; A J Gibb; D Colquhoun
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

9.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

10.  Suramin reverses non-depolarizing neuromuscular blockade in rat diaphragm.

Authors:  R H Henning; A Nelemans; A H Scaf; J Van Eekeren; S Agoston; A Den Hertog
Journal:  Eur J Pharmacol       Date:  1992-05-27       Impact factor: 4.432

View more
  15 in total

1.  Excitatory effect of P2X receptor activation on mesenteric afferent nerves in the anaesthetised rat.

Authors:  A J Kirkup; C E Booth; I P Chessell; P P Humphrey; D Grundy
Journal:  J Physiol       Date:  1999-10-15       Impact factor: 5.182

2.  Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Authors:  R Bültmann; O Dudeck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

3.  Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx.

Authors:  A D Michel; C B Grahames; P P Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

4.  A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat.

Authors:  C Ho; J Hicks; M W Salter
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 5.  New insights on P2X purinoceptors.

Authors:  P P Humphrey; G Buell; I Kennedy; B S Khakh; A D Michel; A Surprenant; D J Trezise
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

6.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Authors:  R Bültmann; H Wittenburg; B Pause; G Kurz; P Nickel; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

7.  PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.

Authors:  S J Charlton; C A Brown; G A Weisman; J T Turner; L Erb; M R Boarder
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 8.  Crossing the pain barrier: P2 receptors as targets for novel analgesics.

Authors:  C Kennedy; T S Assis; A J Currie; E G Rowan
Journal:  J Physiol       Date:  2003-09-26       Impact factor: 5.182

9.  Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors.

Authors:  Sean G Brown; Yong-Chul Kim; Soon-Ai Kim; Kenneth A Jacobson; Geoffrey Burnstock; Brian F King
Journal:  Drug Dev Res       Date:  2001-10-18       Impact factor: 4.360

10.  PPADS: an antagonist at endothelial P2Y-purinoceptors but not P2U-purinoceptors.

Authors:  C Brown; B Tanna; M R Boarder
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.